The Phase II trial by Mutsunori Murahashi et al., targeting KIF20A in advanced biliary tract cancer, has further expanded the horizon, illustrating the vaccine’s clinical benefits through induced specific T-cell responses and prolonged survival [101]. Here, KIF20A is linked to biliary tract neoplasm.